214 related articles for article (PubMed ID: 18044134)
21. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
Simoens S; Decramer M
Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
[TBL] [Abstract][Full Text] [Related]
22. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
[TBL] [Abstract][Full Text] [Related]
23. [Role of moxifloxacin in the treatment of community-acquired pneumonia].
Máthé A; Tóth K; Kovács G
Orv Hetil; 2004 Oct; 145(44):2227-30. PubMed ID: 15626167
[TBL] [Abstract][Full Text] [Related]
24. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
25. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Lamping DL; Schroter S; Marquis P; Marrel A; Duprat-Lomon I; Sagnier PP
Chest; 2002 Sep; 122(3):920-9. PubMed ID: 12226033
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
[TBL] [Abstract][Full Text] [Related]
27. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
Garau J; Fritsch A; Arvis P; Read RC
J Chemother; 2010 Aug; 22(4):264-6. PubMed ID: 20685631
[TBL] [Abstract][Full Text] [Related]
31. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
Landen H; Möller M; Tillotson GS; Kubin R; Höffken G
J Int Med Res; 2001; 29(2):51-60. PubMed ID: 11393349
[TBL] [Abstract][Full Text] [Related]
33. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
34. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
[TBL] [Abstract][Full Text] [Related]
35. Moxifloxacin: a review of its use in the management of bacterial infections.
Keating GM; Scott LJ
Drugs; 2004; 64(20):2347-77. PubMed ID: 15456331
[TBL] [Abstract][Full Text] [Related]
36. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
37. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Martinez FJ
Clin Infect Dis; 2004 May; 38 Suppl 4():S328-40. PubMed ID: 15127366
[TBL] [Abstract][Full Text] [Related]
38. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
[TBL] [Abstract][Full Text] [Related]
39. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
40. Moxifloxacin.
Balfour JA; Wiseman LR
Drugs; 1999 Mar; 57(3):363-73; discussion 374. PubMed ID: 10193688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
